Journal article
SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 and POLARIS-4 studies
SK Roberts, CL Cooper, E Lawitz, KR Reddy, AJ Thompson, S Zeuzem, IM Jacobson, P Ruane, RH Hyland, LM Stamm, L Han, DM Brainard, N Bräu, T Asselah, BE Willems, S Flamm, M Bourlière, GR Foster, EJ Gane, M Manns Show all
Journal of Hepatology | Elsevier BV | Published : 2017